Filing Details
- Accession Number:
- 0000950170-24-014000
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-12 17:51:02
- Reporting Period:
- 2024-02-12
- Accepted Time:
- 2024-02-12 17:51:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1994702 | Kyverna Therapeutics Inc. | KYTX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1867627 | P. Michael Rubin | 7500 Old Georgetown Road, Suite 800 Bethesda MD 20814 | No | No | No | No | |
1972690 | Northpond Ventures Iii, Lp | 7500 Old Georgetown Road, Suite 800 Bethesda MD 20814 | No | No | No | No | |
2010695 | Northpond Ventures Iii Gp, Llc | 7500 Old Georgetown Road, Suite 800 Bethesda MD 20814 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-02-12 | 2,805,426 | $0.00 | 2,805,426 | No | 4 | C | Indirect | By: Northpond Ventures III, LP |
Common Stock | Acquisiton | 2024-02-12 | 450,000 | $22.00 | 450,000 | No | 4 | P | Indirect | By: Northpond Ventures, LP |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | By: Northpond Ventures III, LP |
No | 4 | P | Indirect | By: Northpond Ventures, LP |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Preferred Stock | Disposition | 2024-02-12 | 12,767,776 | $0.00 | 2,805,426 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect |
Footnotes
- Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the "Issuer"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the "Series B Preferred Stock"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the "Common Stock"). The Series B Preferred Stock had no expiration date.
- Northpond Ventures III GP, LLC ("Northpond III LLC") is the general partner of Northpond Ventures III, LP ("Northpond Fund III"), and Michael P. Rubin is the managing member of Northpond III LLC. As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
- Northpond Ventures GP, LLC ("Northpond LLC") is the general partner of Northpond Ventures, LP ("Northpond Fund"), and Michael P. Rubin is the managing member of Northpond LLC. As a result, Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Mr. Rubin disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any.